Triple Screen

The Triple Screen test contains 1 test with 28 biomarkers.

Maternal serum triple screen is used for prenatal screening for Down syndrome (Trisomy 21), Trisomy 18 (Edwards syndrome), and Open Neural Tube Defects (ONTD). This profile includes Alpha-Fetoprotein (AFP), unconjugated Estriol (µE3), and human Chorionic Gonadotropin (hCG). Establishing risk for fetal Down syndrome, using the triple screen achieves a 55-65% detection rate with a 5% false positive rate. Screening for Trisomy 18 detects 60% of affected fetuses with a 0.2% false positive rate. MSAFP screening detects 88% of anencephaly and 79% of open spina bifida with a 3% false positive rate. Normal results do not ensure birth of a normal infant. In addition, 2-3% of newborns have some type of physical or mental defect, many of which may be undetectable with current prenatal diagnostic procedures.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: AFP, Alpha-Fetoprotein (AFP), Maternal Serum, Triple Test


Age Risk Down Syndrome

Calc'D Gestational Age

Cigarette smoker

Collection Date

Date Of Birth

Donor Age: Egg Retrieval

Donor Egg

Edd Determined By

Est'D Date Of Delivery

Estriol Mom

Estriol, Free


HCG, Serum

Hx Of Neural Tube Defects

Insulin Depend Diabetic



Maternal Weight

Mother's Ethnic Origin

MSs Down Syndrome Risk

MSs Trisomy 18 Risk

Number Of Fetuses

Prev Pregnancy Down Synd

Repeat Specimen

Risk For Ontd

*Process times are an estimate and are not guaranteed. The lab may need additional time due to weather, holidays, confirmation/repeat testing, or equipment maintenance.